Viracta Therapeutics Operating Cash Flow Sales Ratio Over Time
| VIRX Stock | USD 0.14 0.01 6.67% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Viracta Therapeutics Performance and Viracta Therapeutics Correlation. Viracta |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viracta Therapeutics. If investors know Viracta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viracta Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.10) | Return On Assets (0.57) | Return On Equity (2.09) |
The market value of Viracta Therapeutics is measured differently than its book value, which is the value of Viracta that is recorded on the company's balance sheet. Investors also form their own opinion of Viracta Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viracta Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viracta Therapeutics' market value can be influenced by many factors that don't directly affect Viracta Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viracta Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viracta Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viracta Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Cash Flow Sales Ratio Analysis
Compare Viracta Therapeutics and related stocks such as Vincerx Pharma, TRACON Pharmaceuticals, and Rallybio Corp Operating Cash Flow Sales Ratio Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VINC | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| RLYB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| TNYA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| LYRA | (5.3376) | (5.3376) | (5.3376) | (5.3376) | (5.3376) | (5.3376) | (5.3376) | (5.3376) | (5.3376) | (90.5965) | (90.5965) | (90.5965) | (31.8305) | (40.6316) | (42.66) |
| TRVI | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| TARA | (3.3887) | (3.3887) | (3.3887) | (3.3887) | (3.3887) | (3.3887) | (3.3887) | (3.3887) | (3.3887) | (3.3887) | (3.3887) | (3.3887) | (3.3887) | (3.05) | (3.2) |
| ALXO | (6.3812) | (6.3812) | (6.3812) | (6.3812) | (6.3812) | (6.3812) | (6.3812) | (6.3812) | (6.3812) | (2.971) | (32.3934) | (32.3934) | (32.3934) | (37.25) | (35.39) |
| CABA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EYPT | (41.1556) | (2.5528) | (4.0807) | (3.0726) | 0.3876 | (10.0716) | (2.7179) | (7.3985) | (2.7841) | (2.7841) | (0.4192) | (1.3562) | (1.57) | 0.0407 | 0.0428 |
| BMEA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| XFOR | (11.6866) | (11.6866) | (11.6866) | (11.6866) | (11.6866) | (11.6866) | (11.6866) | (11.6866) | (11.6866) | (19.606) | (19.606) | (19.606) | (19.606) | (22.55) | (23.67) |
| MREO | 9.7854 | 9.7854 | 9.7854 | 9.7854 | 9.7854 | 9.7854 | 9.7854 | 9.7854 | 376 | 376 | (72.1145) | (0.1437) | (25.7598) | (2.1132) | (2.01) |
| INZY | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| TERN | (41.827) | (41.827) | (41.827) | (41.827) | (41.827) | (41.827) | (41.827) | (41.827) | (41.827) | (41.827) | (41.827) | (41.827) | (41.827) | (37.64) | (39.53) |
| LPTX | (17.3047) | (17.3047) | (17.3047) | (17.3047) | (17.3047) | (17.3047) | (17.3047) | (17.3047) | (17.3047) | (17.3047) | (17.3047) | (23.438) | (23.438) | (26.95) | (28.3) |
| BCYC | (0.6869) | (0.6869) | (0.6869) | (0.6869) | (0.6869) | (0.6869) | (0.6869) | (0.6869) | (3.6544) | (2.0733) | (1.7121) | (1.2648) | (5.9539) | (2.2475) | (2.36) |
| IGMS | (5.4752) | (5.4752) | (5.4752) | (5.4752) | (5.4752) | (5.4752) | (5.4752) | (5.4752) | (5.4752) | (5.4752) | (5.4752) | (5.4752) | (5.4752) | (90.2493) | (94.76) |
| GLUE | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| STOK | (2.5688) | (2.5688) | (2.5688) | (2.5688) | (2.5688) | (2.5688) | (2.5688) | (2.5688) | (2.5688) | (2.5688) | (2.5688) | (2.5688) | (2.5688) | (9.2331) | (9.69) |
Viracta Therapeutics and related stocks such as Vincerx Pharma, TRACON Pharmaceuticals, and Rallybio Corp Operating Cash Flow Sales Ratio description
My Equities
My Current Equities and Potential Positions
| Viracta Therapeutics | VIRX |
| Classification | Pharmaceutical Products |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.14
Additional Tools for Viracta Stock Analysis
When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.